Blood Podcast

In this week's episode, Blood editor Dr. Laura Michaelis interviews Dr. Sabine Eichinger of the Medical University of Vienna, and Dr. Jeanne Palmer of the Mayo Clinic on their latest articles published in Blood highlighting emerging research and treatment strategies in hematology. Dr. Eichinger discusses a prospective study examining the risk of recurrent venous thromboembolism (VTE) in patients with provoked thrombosis, revealing that recurrence rates were higher than previously estimated, particularly among patients with major transient risk factors. Her findings suggest that recurrence risk is not uniform and that anticoagulation duration should be individualized rather than based on a one-size-fits-all approach. Dr. Jeanne Palmer then reviews a Phase II clinical trial of sapablursin, a novel hepcidin mimetic for polycythemia vera, explaining how the agent regulates iron availability to reduce erythropoiesis, decrease phlebotomy requirements, and potentially improve patients' quality of life.Featured Articles: Risk of recurrence in patients with provoked venous thromboembolism: a prospective cohort studySapablursen for erythrocytosis control in patients with polycythemia vera

In this week's episode, Blood editor Dr. Natalie Rosen interviews Dr. Lindsey George, Director of Clinical In Vivo Gene Therapy and an attending physician in the Division of Hematology at Children's Hospital of Philadelphia, and also Dr. Miles Horton and Dr. Thomas Lew of the Royal Melbourne Hospital and Peter McCallum Cancer Center, and the Walter and Eliza Hall Institute of Medical Research on their latest articles published in Blood on the characterization of the prothrombotic mechanisms of recombinant FVIII Aurora and turning immunosuppressants into tools for bidirectional in vivo control. Dr. George discusses "Factor VIII Aurora: a naturally occurring gain-of-function FVIII variant with enhanced FIXa affinity" and Drs. Horton and Lew discuss "Prime editing enables drug-controllable T-cell therapies with clinical immunosuppression".

In this week's episode, Blood editor Dr. Laurie Sehn interviews Dr. Andrew Lane from the Dana-Farber Cancer Institute and Dr. Pooja Khandelwal from the Cincinnati Children's Hospital Medical Center on their latest articles published in Blood on new drug combinations for BPDCN and reduced intestinal dysbiosis after HSCT. Dr. Lane discusses "Tagraxofusp, azacitidine, and venetoclax for blastic plasmacytoid dendritic cell neoplasm" and after, Dr. Khandelwal discusses "Human milk oligosaccharide (2′-FL) modifies the gut microbiome in children after bone marrow transplant".

In this week's episode, Blood editor Dr. Laurie Sehn interviews Dr. Annamaria Aprile of the San Raffaele Telethon Institute for Gene Therapy on her latest article published in Blood titled "Iron overload damages mitochondria and induces metabolic rewiring of hematopoietic stem cells toward glycolysis." Dr. Aprile describes how reducing iron and mitochondrial reactive oxygen species in vivo restores mitochondrial activity, quiescence, and the self-renewal of HSCs. She discusses the therapeutic implications of these findings, focusing on combining iron chelation with a mitochondrial-focused antioxidant to protect or restore stem cell function, a strategy that still needs further testing, including in patient-derived cells.

In this week's episode, Blood editor Dr. Laura Michaelis interviews Dr. Moritz Fürstenau of University Hospital Cologne and Dr. William Dunn of the University of Cambridge on their latest articles published in Blood on CLL and clonal monocytosis. Dr. Fürstenau discusses "Venetoclax combinations in untreated CLL: 5-year results and patient-reported outcomes analysis of the CLL13/GAIA trial" highlighting greater improvements in patient-reported quality of life.  Dr. Dunn discusses "The prevalence and clinical significance of clonal monocytosis" describing how using sex-specific monocyte thresholds and excluding isolated DNMT3A mutations refines the association between CMUS and MN.